Table 1 Clinical trials evaluating combination of epigenetic inhibitors and immunotherapies
From: Leveraging epigenetics to enhance the efficacy of immunotherapy
Epigenetic therapy | Immunotherapy | Cancer type | Phase, Trial ID |
|---|---|---|---|
Histone deacetylase inhibitors (target) | Â | Â | Â |
CXD101 (Pan HDAC) | Nivolumab (PD-1) | Colorectal cancer | I/II, NCT03993626 |
Domatinostat (HDAC1,2,3) | Avelumab (PD-L1) | GI cancer | II, NCT03812796 |
Entinostat (HDAC1,2,3) | Pembrolizumab (PD-1) | Bladder cancer | II, NCT03978624 |
Melanoma | II, NCT03765229 | ||
MDS | I, NCT02936752 | ||
Metastatic uveal melanoma | II, NCT02697630 | ||
| Â | Atezolizumab (PD-L1) | Breast cancer | I/II, NCT03280563 |
| Â | Nivolumab (PD-1) | Cholangiocarcinoma, pancreatic adenocarcinoma | II, NCT03250273 |
| Â | Aldesleukin (IL-2) | Renal cell carcinoma | I/II, NCT01038778 |
| Â | Nivolumab (PD-1), Ipilimumab (CTLA-4) | Breast cancer | I, NCT02453620 |
Mocetinostat (Pan HDAC) | Durvalumab (PD-L1) | NSCLC | I/II, NCT02805660 |
Tinostamustine (Pan HDAC) | Nivolumab (PD-1) | Melanoma | I, NCT03903458 |
Vorinostat (Pan HDAC) | Pembrolizumab (PD-1) | Lymphomas | I, NCT03150329 |
Renal cell carcinoma | I, NCT02619253 | ||
NSCLC | I/II, NCT02638090 | ||
Head and neck | I/II, NCT02538510 | ||
DNA methyltransferase inhibitors | Â | Â | Â |
Azacytidine | Avelumab (PD-L1) | DLBCL | III, NCT02951156 |
| Â | Alemtuzumab (CD52) | Myeloid malignancies | II, NCT02497404 |
| Â | Pembrolizumab (PD-1) | AML | II, NCT02845297 |
AML | II, NCT03769532 | ||
Pancreatic cancer | II, NCT03264404 | ||
MDS | II, NCT03094637 | ||
Oral azacytidine (CC-486) | Pembrolizumab (PD-1) | Ovarian cancer | II, NCT02900560 |
NSCLC | II, NCT02546986 | ||
Melanoma | II, NCT02816021 | ||
Decitabine | Pembrolizumab (PD-1) | T cell lymphomas | II, NCT03240211 |
Lymphomas | I, NCT03445858 | ||
AML | I, NCT03969446 | ||
Breast cancer | II, NCT02957968 | ||
| Â | Anti-PD-1 antibody | Solid tumors | I/II, NCT02961101 |
| Â | Dendritic cell vaccine (NY-ESO-1, MAGE-A1 MAGE-A3) | Pediatric brain tumors | I/II, NCT02332889 |
Guadecitabine | Atezolizumab (PD-L1) | Urothelial carcinoma | II, NCT03179943 |
| Â | Durvalumab (PD-L1) | Liver, pancreatic, bile duct, gallbladder | I, NCT03257761 |
| Â | GVAX (Cell vaccine) | Colon cancer | I, NCT01966289 |
| Â | Ipilimumab (CTLA-4) | Melanoma | I, NCT02608437 |
| Â | Pembrolizumab (PD-1) | Ovarian | II, NCT02901899 |
Prostate, NSCLC | I, NCT02998567 | ||
Histone modifications (target) | Â | Â | Â |
Tazemetostat (EZH2) | Pembrolizumab (PD-1) | Bladder cancer | I/II, NCT03854474 |
CPI-1205 (EZH2) | Ipilimumab (CTLA-4) | Solid tumors | I/II, NCT03525795 |
BMS-986158 (BRD2/3/4, BRDT) | Nivolumab (PD-1) | Advanced tumors | I/II, NCT02419417 |
Multiple combinations | Â | Â | Â |
Azacytidine, entinostat | Nivolumab | NSCLC | II, NCT01928576 |
Azacytidine, venetoclax (Bcl-2) | Pembrolizumab | AML | II, NCT04284787 |
Azacytidine, epacadostat (IDO-1) | Pembrolizumab | Metastatic solid tumors | I/II, NCT02959437 |
Mocetinostat, guadecitabine | Pembrolizumab | Lung cancer | I, NCT03220477 |
Vorinostat, temozolomide | Pembrolizumab | Glioblastoma | I, NCT03426891 |
Vorinostat, tamoxifen | Pembrolizumab | Breast cancer | II, NCT04190056 II, NCT02395627 |
Multiple agents | Multiple agents | Breast, prostrate, pancreas, AML | I, NCT03878524 |
Azacytidine, romidepsin (Pan HDAC) | Pembrolizumab | Colorectal cancer | I, NCT02512172 |
Azacytidine | Tremelimumab (CTLA-4) Durvalumab (PD-L1) | Head and neck cancer | I/II, NCT03019003 |
Decitabine, tetrahydrouridine | Pembrolizumab | NSCLC | I/II, NCT03233724 |